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Objective:Upon completion of this CME activity, successful learners will be able to discuss the incidence of antireflux surgery,
recurrence of gastroesophageal reflux disease after antireflux surgery, and how laparoscopic antireflux surgery compares with
open antireflux surgery.All individuals in the 5 Nordic 
countries who underwent 
primary antireflux surgery in 
2000-2018
Age, comorbidity, and hospital volume influence 90-day 












BACKGROUND & AIMS: Absolute rates and risk factors of short-
term outcomes after antireflux surgery remain largely unknown.
Weaimed to clarify absolute risks and risk factors for poor 90-day
outcomes of primary laparoscopic and secondary antireflux
surgery. METHODS: This population-based cohort study
included patients who had primary laparoscopic or secondary
antireflux surgery in the 5 Nordic countries in 2000-2018. In
addition to absolute rates, we analyzed age, sex, comorbidity,
hospital volume, and calendar period in relation to all-cause 90-
day mortality (main outcome), 90-day reoperation, and pro-
longed hospital stay (2 days over median stay). Multivariable
logistic regression provided odds ratios (ORs) with 95% confi-
dence intervals (95% CI), adjusted for confounders. RESULTS:mong 26,193 patients who underwent primary laparoscopic
ntireflux surgery, postoperative 90-day mortality and 90-day
eoperation rates were 0.13% (n ¼ 35) and 3.0% (n ¼ 750),
espectively. The corresponding rates after secondary antireflux
urgery (n¼ 1618)were 0.19% (n¼ 3) and6.2% (n¼ 94). Higher
ge (56-80 years vs 18-42 years: OR, 2.66; 95% CI 1.03-6.85) and
omorbidity (Charlson Comorbidity Index2 vs 0: OR, 6.25; 95%
I 2.42-16.14) increased risk of 90-day mortality after primary
urgery, and higher hospital volume suggested a decreased risk
highest vs lowest tertile: OR, 0.58; 95% CI, 0.22-1.57). Comor-
idity increased the risk of 90-day reoperation. Higher age and
omorbidity increased risk of prolonged hospital stay after both
primary and secondary surgery. Higher annual hospital volume
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Absolute rates and risk factors of poor short-term
outcomes after antireflux surgery remain largely
unknown, but are important for clinical decision-making
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ATdecreased the risk of prolonged hospital stay after primary surgery
(highest vs lowest tertile: OR, 0.74; 95% CI, 0.67-0.80). CONCLU-
SION: These findings suggest that laparoscopic antireflux surgery
has an overall favorable safety profile in the treatment of gastro-
esophageal reflux disease, particularly in younger patients without
severe comorbidity who undergo surgery at high-volume centers.in patients with gastroesophageal reflux disease (GERD).
NEW FINDINGS
This multinational cohort of primary laparoscopic
(n¼26,193) and secondary (n¼1,618) antireflux surgery,
showed low 90-day mortality (0.13% and 0.19%,
respectively). Following primary surgery, comorbidity
and older age increased 90-day mortality and hospitalKeywords: Gastroesophageal Reflux Disease; GERD; GORD;
Fundoplication; Laparoscopic.
ntireflux surgerywith laparoscopic fundoplication is astay, while higher hospital volume decreased hospital
stay. After secondary surgery, higher age and
comorbidity increased hospital stay.
LIMITATIONS
The main limitation of the present study is the lack of
direct data on covariates that might contribute to
confounding, such as obesity and smoking.
IMPACT
Antireflux surgery is a safe treatment option for GERD,
particularly in younger patients without severe
comorbidity who undergo surgery at high-volume centers.Aviable treatment option for selected patients with
objectively confirmedgastroesophageal refluxdisease (GERD),
particularly for those who do not respond adequately to
antireflux therapywith aprotonpump inhibitor (PPI) ordonot
want or tolerate long-term PPI use. Compared with PPI ther-
apy, antireflux surgery seems to be superior regarding reflux
symptom control, esophageal acid exposure time, quality of
life, and cost-effectiveness.1,2 However, apart from the risk of
postoperative recurrence of reflux symptoms,3,4 antireflux
surgery carries a risk of serious complications,1,5 which has
contributed to its decreased use.5–7 The reported post-
operative mortality rates in Western populations are up to
0.6% after primary laparoscopic antireflux surgery and up to
0.8% after secondary antireflux surgery, and severe nonlethal
complications occur in up to 4.8% of cases.3,5,8–12
However, the validity of these estimates is unclear for a
number of reasons. First, they are based on few or no deaths,
leading to low statistical precision. Second, most studies have
assessed 30-day outcomes or in-hospital mortality, although
90-day outcomes are now regarded as more valid because of
developments in perioperative health care and improve-
ments in rescue strategies. Third and last, selection bias is a
concern because few studies have been population-based.
There is little knowledge about risk factors for poor
postoperative outcomes after primary antireflux surgery
and less so for secondary antireflux surgery. In an attempt
to overcome these limitations of the existing evidence, we
examined the absolute risks and risk factors for poor 90-day
outcomes of primary laparoscopic antireflux surgery and
secondary antireflux surgery from a modern period in a
population-based multinational cohort.Abbreviations used in this paper: CI, confidence interval; GERD, gastro-
esophageal reflux disease; IQR, interquartile range; NordASCo, Nordic
Antireflux Surgery Cohort; OR, odds ratio; PPI, proton pump inhibitor.
Most current article
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This population-based cohort study included all individuals
aged between 18 and 80 years who had undergone elective
primary (first) laparoscopic (no open surgery) antireflux sur-
gery for GERD according to any of the national patient regis-
tries in the 5 Nordic countries of Denmark, Finland, Iceland,
Norway, or Sweden. The overall study period was January 1,
2000, to December 31, 2018, but with different start and end
years for each country (2000–2014 in Denmark, 2000–2018 in
Sweden, 2000–2018 in Finland, and 2008–2013 in Norway).
Participants were included if the primary laparoscopic
procedure was conducted at least 90 days before the end of the
study period (December 31, 2018) to ensure 90 days of follow-up for each patient. A subcohort included patients who un-
derwent elective secondary antireflux surgery (laparoscopic or
open), defined as a second antireflux surgery procedure after a
primary laparoscopic antireflux procedure.
The study investigated absolute rates of mortality and
reoperation within 90 days of surgery, risk factors for the out-
comes all-cause mortality (main), reoperation, and prolonged
hospital stay within 90 days of primary laparoscopic antireflux
surgery, and risk factors for reoperation and prolonged hospital
stay within 90 days of secondary antireflux surgery (there were
too few deaths after secondary antireflux surgery to allow ana-
lyses of risk factors for this outcome). The studywas approved by
all relevant ethical review boards, data inspectorates, and
governmental agencies in the 5 Nordic countries.13
Cohort
The study cohort was an updated version of the Nordic
Antireflux Surgery Cohort (NordASCo), which has been
described in detail in a separate cohort profile paper.13 In brief,
NordASCo consists of merged data from well-established and
nationwide health data registries in the Nordic countries, con-
sisting of patient registries, cancer registries, and cause of death
registries.13 The similarity in structure of these registries and the
system of personal identity codes of all Nordic residents allowed
precise linkages of individuals’ data between the registries.13,14





ATAll patients in NordASCo had a GERD diagnosis or elective
antireflux surgery in any of the Nordic patient registries (with
codes defined in Supplementary Table 1). Complete national
coverage of the patient registries was reached in 1970s
(Finland), 1978 (Denmark), 1987 (Sweden), 1999 (Iceland), and
2008 (Norway). The data in these registries have high validity,
with most diagnoses and surgical procedures having a positive
predictive value close to 100%.15–17 Patients who underwent
paraesophageal repair without a concomitant antireflux surgery
procedure were not included, and patients with incarcerated
hernia (International Classification of Diseases, Tenth Revision,
codes K44.0, K44.1) or those who underwent emergency anti-
reflux surgery (Nordic Medico-Statistical Committee Classifica-
tion of Surgical Procedures code ZXD00) were excluded.
Exposures
The analyses assessed 5 potential risk factors (exposures)
for the study outcomes: age at surgery (categorized into 3
similarly sized groups; ie, tertiles), sex (male or female), co-
morbidity (Charlson Comorbidity Index 0, 1, or 2), annual
hospital volume of primary laparoscopic antireflux surgery
(tertiles), and calendar period (tertiles). The Charlson Comor-
bidity Index was developed for assessing how comorbidity in-
fluences outcomes after surgical procedures, and the most
recent and well-validated version of this index was used in this
study.18,19 The index was based on diagnoses recorded in the
patient registries up to 3 years before inclusion into the cohort.
This time restriction was made to consider only the most
relevant comorbidities at the time of antireflux surgery.
Annual hospital volume of primary laparoscopic antireflux
surgery and secondary antireflux surgery was calculated using a
4-year moving average, counting the procedures at each hospital
during the year of surgery and the 3 previous years. The analyses
of annual hospital volume did not include patients from Iceland
or Norway, because of the lack of such data in these countries.
Outcomes
The main outcome was all-cause 90-day postoperative
mortality. The cause of death registries provided causes of death
and death dates through December 31, 2018, with virtually
100% complete and accurate recording.14,20 A secondary
outcome was reoperation within 90 days of surgery. The specific
procedures used for defining reoperation are presented in
Supplementary Table 2. The other secondary outcome was
prolonged hospital stay, defined as 2 days longer than the
median length of hospital stay after primary laparoscopic or
secondary antireflux surgery, calculated separately. Length of
hospital stay was assessed using admission and discharge dates
in the patient registries. Any new admission to in-hospital care
within 1 day of the discharge datewas regarded as a continuation
of the initial postoperative hospital stay.
Statistical Analysis
The absolute rates of mortality and reoperation were calcu-
lated as frequencies, and length of hospital staywas calculated as
the median with the interquartile range (IQR). To assess the in-
fluence of the 5 potential risk factors on the outcomes, multi-
variable logistic regression was used to calculate odds ratios
(OR)with 95%confidence intervals (CIs). TheORswere adjusted
for age at surgery (categorized into tertiles), sex (male or female),
comorbidity (Charlson Comorbidity Index 0, 1, or 2), calendarperiod (tertiles), and country (Finland, Sweden, or Denmark, and
Iceland and Norway combined). In the analysis of prolonged
hospital stay, where the statistical power was higher than for the
other outcomes, the influence of the continuous variables of age,
year of surgery, and annual hospital volume on the odds of the
outcome was modeled with cubic splines, adjusted for the other
exposures. These results are reported in graphs as probabilities
using the following reference values: age 43 to 55 years,male sex,
Charlson Comorbidity Index 0, calendar year 2000 to 2003, and
Finland. All statistical analyses were conducted using IBM SPSS
Statistics 24 software (IBM Corp, Armonk, NY) and were guided
by an experienced biostatistician (G.S.).
Results
Patients
The study cohort included 26,193 patients who had
undergone elective primary laparoscopic antireflux surgery
for GERD, and the subcohort included 1618 patients who
had undergone elective secondary antireflux surgery.
Characteristics of the study participants are presented in
Table 1. In the primary laparoscopic antireflux surgery
cohort, the median age was 50 years (IQR, 39–59 years),
53% were women, and 85% had no comorbidity included in
the Charlson Comorbidity Index. In the secondary antireflux
surgery subcohort, the median age was 53 years (IQR, 43–
62 years), 57% were women, and 79% had no comorbidity.
Mortality
The absolute all-cause 90-day mortality rate was 0.13%
(n ¼ 35) after primary laparoscopic antireflux surgery and
0.19% (n ¼ 3) after secondary antireflux surgery. The cor-
responding rates for 30-day mortality were 0.08% (n ¼ 22)
and 0.06% (n ¼ 1), respectively. The most frequent causes
of death were secondary to cardiovascular disease and
suicide or intoxication (Table 2).
Table 3 presents the ORs of 90-day all-cause mortality in
the primary laparoscopic antireflux surgery cohort. The
adjusted ORs were increased in patients of higher age
(highest vs lowest tertile: OR, 2.66; 95% CI, 1.03–6.85) and
in those with comorbidity (Charlson Comorbidity Index 2
vs 0: OR, 6.25; 95% CI, 2.42–16.14), whereas sex did not
influence the risk. The point estimates decreased with
higher hospital volume (highest vs lowest tertile: OR, 0.58;
95% CI, 0.22–1.57) and increased over calendar periods, but
none of these estimates reached statistical significance.
Reoperation
The 90-day reoperation rate was 3.0% (n ¼ 750) after
primary laparoscopic antireflux surgery and 6.2% (n ¼ 94)
after secondary antireflux surgery.
Comorbidity was associated with an increased OR of
reoperation within 90 days of primary laparoscopic antire-
flux surgery (Charlson Comorbidity Index 2 vs 0: OR, 1.47;
95% CI, 0.97–2.23; and Charlson Comorbidity Index 1 vs 0:
OR, 1.29; 95% CI, 1.05–1.58). There were no statistically
significant associations between the other exposures (age,
sex, hospital volume, or calendar periods) and the risk of
reoperation (Table 3).
Table 1.Characteristics of Patients Who Underwent Primary
Laparoscopic or Secondary Antireflux Surgery in a









Number (%) Number (%)
Total 26,193 (100) 1618 (100)
Age (tertilesa)
Lowest 8374 (33.4) 515 (31.8)
Intermediate 9073 (34.6) 551 (34.1)
Highest 8746 (32.0) 552 (34.1)
Sex
Male 13,841 (47.2) 695 (43.0)
Female 12,352 (52.8) 923 (57.0)
Charlson Comorbidity Index
0 22,325 (85.2) 1279 (79.0)
1 3265 (12.5) 277 (17.1)
2 603 (2.3) 62 (3.8)
Annual hospital volumeb (tertilesc)
Lowest 7899 (33.3) 484 (33.1)
Intermediate 7848 (33.1) 497 (34.0)
Highest 7943 (33.5) 481 (32.9)
Calendar period (tertilesd)
Earliest 9023 (34.4) 516 (31.9)
Intermediate 8744 (33.4) 559 (34.5)
Latest 8426 (32.2) 543 (33.6)
Country
Denmark 3119 (11.9) 272 (16.8)
Finland 13,255 (50.6) 782 (48.3)
Iceland 1300 (4.96) 101 (6.24)
Norway 1203 (4.59) 55 (3.40)
Sweden 7316 (27.9) 408 (25.2)
30–day mortality 22 (0.08) 1 (0.06)e
90–day mortality 35 (0.13) 3 (0.19)
Reoperation within 90 days
of surgeryf
750 (3.0) 94 (6.2)
aPrimary surgery: lowest, 18–42 years; intermediate, 43–55
years; highest, 56–80 years; secondary surgery: lowest, 18–
46 years; intermediate, 47–58 years; highest, 59–80 years.
bRestricted to 23,690 participants from Denmark, Finland,
and Sweden with data on hospital volume.
cPrimary surgery: lowest 24, intermediate 25–47, highest
>47; secondary surgery: lowest 26, intermediate 27–47,
highest >47.
dPrimary surgery: lowest 2000–2003, intermediate 2004–
2008, highest 2009–2018; secondary surgery: lowest 2000–
2006, intermediate 2007–2011, highest 2012–2018.
eObserved study participant is not from Denmark.
fRestricted to 24,893 participants from Denmark, Finland,
Norway, and Sweden with data on reoperation.











Respiratory disease 4 (11)
Cardiovascular disease 8 (23)
Gastrointestinal diseaseb 6 (17)
Suicide or intoxication 7 (20)
Cancer <3a
aDanish law does not allow reporting of absolute numbers <3
in studies including participants from Danish health registries.
bIncludes diagnosis codes representing pancreatitis, peritonitis,
gastrointestinal bleeding, and gastrointestinal perforation.
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ATThere were no statistically significant associations for
any of the 5 exposures in relation to the risk of reoperation
within 90 days of secondary antireflux surgery (Table 4).Prolonged Hospital Stay
The median length of hospital stay was 3 days (IQR, 2–4
days) after primary laparoscopic antireflux surgery and 4
days (IQR, 2–6 days) after secondary antireflux surgery.
Prolonged hospital stay (2 days longer than the median
length of hospital stay) was observed in 5252 patients
(20%) after primary surgery and in 477 patients (29%)
after secondary surgery.
Table 3 gives the adjusted ORs of prolonged hospital stay.
After primary laparoscopic antireflux surgery, the ORs
increasedwith older age (age 56–80 vs 18–42 years: OR, 1.48;
95% CI, 1.37–1.61), and an upward deflection in probability
was found around the age of 60 years (Figure 1). Higher
hospital volume was followed by a decreased OR (highest vs
lowest tertile: OR, 0.74; 95% CI, 0.67–0.80), and the proba-
bility of prolonged hospital stay declined in a seemingly
continuous manner with increasing hospital volume
(Figure 2). The OR was slightly higher in women compared
with men (OR, 1.09; 95% CI, 1.02–1.16). Comorbidity was
associated with increased ORs (Charlson Comorbidity Index
2 vs 0: OR, 2.38; 95% CI, 1.98–2.85). The ORs of prolonged
hospital stay decreased over calendar periods (2009–2018 vs
2000–2003: OR, 0.48; 95% CI, 0.44–0.52), which seemed to
plateau around the year 2010 (Figure 3).
After secondary antireflux surgery, older age and co-
morbidity were associated with increased ORs of prolonged
hospital stay, whereas later calendar period was associated
with decreased ORs, and sex and hospital volume did not
influence the ORs of prolonged hospital stay (Table 4).
Discussion
This population-based study shows low 90-day rates of
all-cause mortality and reoperation and short median hos-
pital stays after primary laparoscopic and secondary
Table 3.Odds Ratios and 95% Confidence Intervals of 90-Day Mortality, 90-Day Reoperation, and Prolonged Hospital Stay
After Primary Laparoscopic Antireflux Surgery
Variable
90-day mortality 90-day reoperation Prolonged hospital staya
Patients (n)
Adjusted ORb
(95% CI) Patients (n)
Adjusted ORb




18–42 6 1.00 [Reference] 241 1.00 [Reference] 1504 1.00 [Reference]
43–55 6 0.87 (0.28–2.73) 245 0.92 (0.78–1.11) 1694 1.06 (0.98–1.15)
56–80 23 2.66 (1.03–6.85) 264 0.98 (0.81–1.18) 2054 1.48 (1.37–1.61)
Sex
Male 15 1.00 [Reference] 389 1.00 [Reference] 2630 1.00 [Reference]
Female 20 1.08 (0.54–2.14) 361 1.04 (0.89–1.20) 2622 1.09 (1.02–1.16)
Charlson Comorbidity Index
0 21 1.00 [Reference] 608 1.00 [Reference] 4200 1.00 [Reference]
1 8 1.93 (0.84–4.44) 117 1.29 (1.05–1.58) 845 1.54 (1.40–1.68)
2 6 6.25 (2.42–16.14) 25 1.47 (0.97–2.23) 207 2.38 (1.98–2.85)
Annual hospital volumec
24 13 1.00 [Reference] 252 1.00 [Reference] 1560 1.00 [Reference]
25–47 14 0.99 (0.43–2.25) 224 0.84 (0.70–1.02) 2184 1.05 (0.96–1.14)
>47 6 0.58 (0.22–1.57) 252 1.10 (0.91–1.32) 1289 0.74 (0.67–0.80)
Calendar period (in years)
2000–2003 6 1.00 [Reference] 229 1.00 [Reference] 2229 1.00 [Reference]
2004–2008 10 1.51 (0.55–4.20) 246 1.07 (0.89–1.29) 1587 0.61 (0.56–0.65)
2009–2018 19 2.33 (0.91–5.98) 275 1.15 (0.95–1.38) 1436 0.48 (0.44–0.52)
aDefined as 2 days longer than the median length of hospital stay after surgery.
bAdjusted for age, sex, Charlson Comorbidity Index, calendar period, and country.
cRestricted to 23,690 participants from Denmark, Finland, and Sweden with data on hospital volume.





ATantireflux surgery. For primary laparoscopic antireflux sur-
gery, comorbidity increased the risk of all postoperative
outcomes, older age increased the risk of 90-day mortality
and prolonged hospital stay, and male sex, higher annual
hospital volume, and later calendar period decreased the risk
of prolonged hospital stay. For secondary antireflux surgery,
older age and comorbidity increased the risk of prolonged
hospital stay, and later calendar period decreased this risk.
Strengths of this study include the population-based design,
the large sample size, the use of data with high quality and
validity, and the complete follow-up. Because the study en-
compassed virtually all patients who underwent primary lapa-
roscopic or secondary antireflux surgery in any of the 5 Nordic
countries from year 2000 onward, it was possible to reflect on
unselected clinical practice in a modern era and to support
generalization of the findings to other Western populations.
There are also weaknesses. Despite the adjustment for
several confounders, residual or unmeasured confounding
cannot be ruled out. This might be particularly relevant for
the variables of body mass index and tobacco smoking,
where we did not have direct data in the registries, because
these can increase the risk of postoperative complications.
However, tobacco smoking was indirectly controlled for by
adjustment for the Charlson Comorbidity Index, which in-
cludes diseases closely associated with heavy tobacco
smoking (eg, chronic obstructive pulmonary disease).
Although individuals who underwent antireflux surgery
due to incarcerated hernia or emergency surgery wereexcluded, another limitation is that factors that might in-
crease the technical difficulty of the antireflux surgery, such
as visceral adiposity and abdominal adhesions from previ-
ous surgery, could not be accounted for. Yet, the influence of
obesity was counteracted by the adjustment for Charlson
Comorbidity Index, which includes diagnoses closely related
to obesity, such as diabetes type 2.21 Data on specific types
of antireflux surgery techniques were not available, but the
dominant techniques in the Nordic countries are laparo-
scopic Nissen (360 wrap) and Toupet (270 posterior
wrap). Finally, despite the large sample size, the statistical
power was low in some of the analyses.
Few studies have investigated the absolute rate of
mortality within 90 days of primary laparoscopic antireflux
surgery, and even fewer of secondary antireflux surgery,
and the largest studies have had insufficient sample sizes for
robust analyses. Nevertheless, the 90-day mortality rate
(0.13%) after primary laparoscopic antireflux surgery in the
present study was similar to a Swedish study in 1997 to
2013 of 8947 patients of (0.08% [n ¼ 7]).5 However, this
rate was higher in a Danish study in 2000 to 2017 of 3717
patients (0.6% [n ¼ 22]),8 which could be due to the in-
clusion of emergency surgery and surgery due to incarcer-
ated hernia, which were excluded in the present study. The
same Danish study also reported 90-day mortality (0.6% [n
< 5]) in 541 patients who underwent secondary antireflux
surgery, whereas a Swedish study reported 0 deaths in 549
patients after such surgery.3,8 While these previous studies
Table 4.Odds Ratios and 95% Confidence Intervals of 90-Day Reoperation and Prolonged Hospital Stay After Secondary
Antireflux Surgery
Variable










18–46 34 1.00 [Reference] 141 1.00 [Reference]
47–58 32 0.91 (0.55–1.51) 146 0.93 (0.70–1.23)
59–80 28 0.79 (0.46–1.36) 190 1.57 (1.18–2.08)
Sex
Male 47 1.00 [Reference] 201 1.00 [Reference]
Female 47 0.79 (0.51–1.21) 276 1.01 (0.81–1.27)
Charlson Comorbidity
Index
0 72 1.00 [Reference] 1279 1.00 [Reference]
1 20 1.41 (0.83–2.38) 277 1.23 (0.92–1.64)
2 2c 0.63 (0.15–2.67) 62 1.97 (1.15–3.38)
Annual hospital volumed
<26 30 1.00 [Reference] 129 1.00 [Reference]
27–47 29 0.93 (0.53–1.62) 183 1.15 (0.86–1.55)
>47 31 0.99 (0.57–1.72) 150 0.97 (0.71–1.31)
Calendar period (in years)
2000–2006 32 1.00 [Reference] 191 1.00 [Reference]
2007–2011 29 0.86 (0.50–1.48) 164 0.56 (0.43–0.73)
2012–2018 33 1.03 (0.60–1.74) 122 0.38 (0.29–0.51)
aDefined as 2 days longer than the median length of hospital stay after surgery.
bAdjusted for age, sex, Charlson Comorbidity Index, calendar period, and country.
cObserved study participants are not from Denmark.
dRestricted to 1462 participants from Denmark, Finland, and Sweden with data on hospital volume.
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ATused data that were in part included in the cohort of the
present study, the present study has an unselected cohort
from a more recent period and a much larger sample size,
providing reassurance in the low mortality rates found.
To our knowledge, this is the first study examining risk
factors of short-term mortality after antireflux surgery. This
gap of knowledge is probably due to the low mortality rates,
which require very large-scale studies. The risk of 90-dayFigure 1. Probability (black line) with 95% confidence in-
tervals (grey area) of prolonged hospital stay by age at sur-
gery after primary laparoscopic antireflux surgery.mortality after primary laparoscopic antireflux surgery
was greatly increased in patients of older age and with co-
morbidity and was possibly decreased by higher annual
volume (statistically nonsignificant), whereas sex, hospital
volume, and calendar period did not reach statistical sig-
nificance in influencing this risk.
The association with age seemed to start from 60 years.
The associationswith age and comorbidity are probably due toFigure 2. Probability (black line) with 95% confidence in-
tervals (grey area) of prolonged hospital stay by hospital
volume after primary laparoscopic antireflux surgery.
Figure 3. Probability (black line) with 95% confidence in-
tervals (grey area) of prolonged hospital stay over time after
primary laparoscopic antireflux surgery.





AThigher frailty and likelihood of life-threatening postoperative
complications. The potential association with higher annual
volume indicates a beneficial influence of the experience of the
surgeon and the surgical team on postoperative outcomes.
This may be explained by stricter selection of surgical candi-
dates, more specialized surgeons conducting these proced-
ures, and more tailored perioperative healthcare.
Only 1 previous study, from Sweden (n ¼ 8947), has
investigated the 90-day reoperation rate after primary
laparoscopic antireflux surgery and found a lower rate
(0.4%) than in the present study (3.0%).5 This difference is
probably due to the broader inclusion of reoperation codes
in the present study. No other study has investigated the 90-
day reoperation rate after secondary antireflux surgery, but
the present study indicates a rather low rate.
The median length of hospital stay after primary laparo-
scopic antireflux surgery and secondary antireflux surgery
was similar to some other studies.3,5 The present study found
an increased risk of prolonged hospital stay in patients with
older age and comorbidity, and a decreased risk in high-
volume hospitals and with later calendar period. Older age
and comorbidity predispose to a longer hospital stay in
general, and these patients also have an increased risk of
postoperative complications and slower recovery compared
with younger and more fit patients. The lower risk of pro-
longed hospital stay after primary antireflux surgery in high-
volume hospitals may be explained by the same reasons as
those described above. The shorter hospital stays with later
calendar period could be at least partly explained by the
development in perioperative health care.
Compared with the other Nordic countries included in
the study cohort, Finland had a higher number of antireflux
surgery patients, which is mainly explained by the differ-
ences in the start and end years of each country’s contri-
bution to the study cohort. The remaining slightly higher
rate of antireflux surgery in Finland is well in line with the
findings of previous studies on antireflux surgery trends in
the Nordic countries.5,7,11
The similar rates of 90-day mortality and prolonged hos-
pital stay after primary and secondary antireflux surgery areprobably due to referrals to more specialized high-volume
centers for secondary surgery and a reflection of clinical se-
lection of more fit patients for secondary surgery instead of
advising antireflux medication. Additionally, all study partici-
pants who underwent secondary antireflux surgery did so
after laparoscopic primary antireflux surgery, which results in
less scarring and adhesions compared with open surgery.
Some studies have suggested similar or slightly superior
reflux control comparing antireflux surgery and PPI in the
treatment of GERD,22–24 and a recent population-based cohort
study from our group found that only a limited proportion
(17.7%) of patients with GERD had reflux recurrence after
primary laparoscopic antireflux surgery.4 Although the pre-
sent study suggests that severe complications after antireflux
surgery are rare, they do exist, which is not the case after
initiation of PPI treatment. Therefore, in view of the benign
nature of GERD and the availability of effective antireflux
medicationwith PPIs,1,25–27 caution should be exercisedwhen
considering antireflux surgery as a treatment option for GERD
in patients with risk factors for poor postoperative outcomes,
such as age>60 years and serious comorbidity, as found in the
present study. Nonetheless, in patients with objectively
confirmed GERD without these risk factors, laparoscopic
antireflux surgery at high-volume centers is a safe treatment
option. Finally, the finding of suicide or intoxication as causes
of 90-daymortality after antireflux surgery suggests a value of
psychologic evaluation in selected patients.
Conclusion
This population-based multinational cohort study in-
dicates that laparoscopic antireflux surgery is an overall safe
treatment option of GERD and that risk of poor short-term
outcomes may be reduced by centralization to high-
volume specialized centers and by selection of patients
aged <60 years without severe comorbidity.
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